Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
BioCryst and Takeda Pharmaceuticals USA, Inc.
Description:
Hereditary angioedema (HAE) is a rare autosomal dominant condition
characterized by recurrent attacks of edema at different locations
of the body. This potentially life-threatening disease affects
approximately 1 in 67,000 individuals, with no identified
differences in sex or ethnicity. HAE is characterized by recurrent
edema attacks and the cutaneous attacks can be disabling, with the
skin, gastrointestinal tract, and upper airways are most commonly
affected and with a persistent risk to the patient of acute events
of laryngeal swelling that may prove fatal if not treated in a
timely manner. Angioedema in general can be confused with cellulitis,
Graves disease, blepharochalasis, eosinophilic fasciitis, or
amyloidosis which can lead to delays in diagnosis, and inappropriate
treatment poses the risk of adverse events, unnecessary surgical
interventions, a higher burden of misery, and a potentially higher
rate of morbidity and mortality. Fortunately for patients with HAE,
novel therapies have recently become available in the past few years
that have shown improved efficacy and safety with improved
administration methods. Additionally, new monoclonal antibody
therapies targeted at younger HAE populations are on the horizon.
With these new options comes a knowledge gap among physician medical
directors, pharmacists, immunologists and nurse case managers as the
treatment paradigm is growing. For this reason, it is critical that
these HCPs are educated and updated on these emerging options and
strategies for their implementation into the treatment paradigm,
including throughout formulary and health plan discussions, which
will ultimately improve patient outcomes in the HAE patient
population.
Upon completion of this
activity, participants will be able to:
-
Evaluate the clinical and economic
burden of hereditary angioedema (HAE) in terms of drug
utilization, adverse event management, and hospitalizations
-
Characterize the diagnosis and
background of HAE and the significance of early intervention
-
Assess the safety and efficacy of
available and emerging treatment options for HAE including
on-demand therapies, short-term prophylaxis, and long-term
prophylaxis
-
Analyze the emerging role of
monoclonal antibody treatments in younger populations in the
management of HAE
-
Review the evolving role of oral
therapy in the prevention of HAE attacks
-
Explore the need for individualized
treatment and the role of the managed care professional in
patient and provider education, especially around younger
populations, for effective HAE management
|
Faculty: |
William R. Lumry, MD
Clinical Professor of Internal Medicine
University of Texas Southwestern Medical School
Medical Director, AARA Research Center
Private Practice, Allergy and Asthma Specialists of
Dallas |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Lumry has served as a consultant for Astria,
BioCryst, Biomarin, CSL Behring, Express Scripts/CVS,
Fresenius Kabi, Intellia, Kalvista, Magellan, Optum,
Pharming, Pharvaris, and Shire/Takeda. He has served as
a speaker for AstraZeneca, BioCryst, CSL Behring,
Grifols, GlaxoSmithKline, Optinose, Pharming,
Shire/Takeda, and Sanofi/Regeneron. He has received
grant/research support from Astria, BioMarin, CSL
Behring, Intellia, Grifols, Ionis, Kalvista, and
Shire/Takeda. His presentation has been reviewed for any
bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by
educational grants from
BioCryst and Takeda Pharmaceuticals USA, Inc.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |